journal
https://read.qxmd.com/read/38198117/correction-to-association-between-antidiabetic-drugs-and-delirium-a-study-based-on-the-adverse-drug-event-reporting-database-in-japan
#21
Yukiko Ishibashi, Rintaro Sogawa, Kenji Ogata, Ayaka Matsuoka, Haruna Yamada, Toru Murakawa-Hirachi, Yoshito Mizoguchi, Akira Monji, Chisato Shimanoe
No abstract text is available yet for this article.
January 10, 2024: Clinical Drug Investigation
https://read.qxmd.com/read/38198116/demystifying-dry-powder-inhaler-resistance-with-relevance-to-optimal-patient-care
#22
REVIEW
Toby G D Capstick, Sanjay Gudimetla, David S Harris, Rachel Malone, Omar S Usmani
The selection of an inhaler device is a key component of respiratory disease management. However, there is a lack of clarity surrounding inhaler resistance and how it impacts inhaler selection. The most common inhaler types are dry powder inhalers (DPIs) that have internal resistance and pressurised metered dose inhalers (pMDIs) that use propellants to deliver the drug dose to the airways. Inhaler resistance varies across the DPIs available on the market, depending largely on the design geometry of the device but also partially on formulation parameters...
January 10, 2024: Clinical Drug Investigation
https://read.qxmd.com/read/38170348/antibiotic-associated-acute-kidney-injury-among-older-adults-a-case-crossover-study
#23
JOURNAL ARTICLE
Tichawona Chinzowu, Te-Yuan Chyou, Prasad S Nishtala
BACKGROUND AND OBJECTIVES: Drug-related acute kidney injury is quite common in older adults. The associated drugs, including antibiotics, are often co-prescribed. The objective of this study was to ascertain antibiotic-associated acute kidney injury (AKI) in older adults aged 65 years or above in New Zealand using a case-crossover study design. METHODS: The International Statistical Classification of Diseases and Related Health Problems, tenth revision, Australian modification code N17...
January 3, 2024: Clinical Drug Investigation
https://read.qxmd.com/read/38036930/key-drivers-of-coagulation-factor-use-in-von-willebrand-disease-during-hospitalization-an-overview-of-the-french-berhlingo-cohort
#24
JOURNAL ARTICLE
Valérie Horvais, Philippe Beurrier, Vincent Cussac, Brigitte Pan-Petesch, Solène Schirr-Bonnans, Johann Rose, Sophie Bayart, Catherine Ternisien, Marc Fouassier, Marianne Sigaud, Antoine Babuty, Nicolas Drillaud, Benoît Guillet, Marc Trossaërt
BACKGROUND: Von Willebrand disease (VWD) is the most common inherited bleeding disorder. However, studies of hospitalisation patterns with replacement treatment are scarce. OBJECTIVES: The aim of this study was to investigate the current therapeutic management of VWD and determine the key drivers of coagulation factor uses in patients during hospitalisation. METHODS: Hopscotch-WILL was a multi-centric retrospective study conducted over a 48-month period in any patients with VWD...
January 2024: Clinical Drug Investigation
https://read.qxmd.com/read/38135802/association-between-antidiabetic-drugs-and-delirium-a-study-based-on-the-adverse-drug-event-reporting-database-in-japan
#25
JOURNAL ARTICLE
Yukiko Ishibashi, Rintaro Sogawa, Kenji Ogata, Ayaka Matsuoka, Haruna Yamada, Toru Murakawa-Hirachi, Yoshito Mizoguchi, Akira Monji, Chisato Shimanoe
BACKGROUND AND OBJECTIVE: Several associations between diabetes mellitus and delirium have been reported; however, they have been inconsistent, and evidence on the effects of antidiabetic medications on delirium is also limited. This study aimed to investigate whether the use of antidiabetic drugs is a risk factor for delirium development. METHODS: Using the Japanese Adverse Event Reporting Database, we analyzed 662,899 reports between 2004 and 2022. Reporting odds ratios (RORs) and 95% confidence intervals (CIs) for delirium associated with diabetes and using each antidiabetic medication were calculated after adjusting for potential confounders...
December 23, 2023: Clinical Drug Investigation
https://read.qxmd.com/read/38114780/real-world-effectiveness-and-safety-of-baricitinib-in-patients-with-atopic-dermatitis
#26
LETTER
Egídio Freitas, Maria João Paiva Lopes, Maria João Cruz, Diogo Sousa, Ana Clara Valente, Bruno Duarte, Laetitia Teixeira, Gilberto Rosas, Mónica Caetano, Alberto Mota, Paulo Filipe, Tiago Torres
No abstract text is available yet for this article.
December 19, 2023: Clinical Drug Investigation
https://read.qxmd.com/read/38112942/food-effect-on-the-pharmacokinetics-of-vc004-a-tropomyosin-receptor-kinase-inhibitor-a-randomized-crossover-trial-in-healthy-chinese-subjects
#27
JOURNAL ARTICLE
Linlin Hu, Qiuyue Sun, Lu Tang, Mingmin Cai, Wei Qian, Ting Dou, Huiping Wang, Yong Wu, Yongqiang Liu
BACKGROUND AND OBJECTIVE: VC004 is a novel next-generation tropomyosin receptor kinase (TRK) inhibitor that is approved for the treatment of advanced or metastatic NTRK fusion-positive solid tumors and abrogated the drug resistance of the first-generation TRK inhibitors. The objective of the present study was to evaluate the effect of food on the pharmacokinetics and safety of VC004. METHODS: The study was a randomized, open-label, two-period crossover, single-dose, phase I clinical trial...
December 19, 2023: Clinical Drug Investigation
https://read.qxmd.com/read/38105393/comparison-of-long-term-effectiveness-and-safety-of%C3%A2-upadacitinib%C3%A2-for-atopic-dermatitis-between-dupilumab-exposed-and-dupilumab-na%C3%A3-ve-patients
#28
JOURNAL ARTICLE
Maddalena Napolitano, Silvia Mariel Ferrucci, Luciano Foggia, Katharina Hansel, Elena Pezzolo, Luca Stingeni, Elettra Antonelli, Vincenzo Picone, Cataldo Patruno
BACKGROUND AND OBJECTIVES: Upadacitinib is an oral selective Janus kinase-1 inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD) in patients [Formula: see text] 12 years of age. In real life, upadacitinib currently represents a valid therapeutic option for patients failing available systemic therapies, in particular patients who discontinued dupilumab because of lack of efficacy or occurrence of adverse events. The objectives of the present study were to compare the effectiveness and safety of upadacitinib in patients affected by AD who had previously failed dupilumab therapy versus biologic naïve patients...
December 17, 2023: Clinical Drug Investigation
https://read.qxmd.com/read/38104048/cost-effectiveness-of-tofacitinib-for-the-treatment-of-active-ankylosing-spondylitis-in-greece
#29
JOURNAL ARTICLE
George Gourzoulidis, Argyro Solakidi, Marina Psarra, Eleni Nikitopoulou, Charalampos Tzanetakos
BACKGROUND AND OBJECTIVE: Ankylosing spondylitis is a chronic, progressive, inflammatory, multidimensional, musculoskeletal disease primarily involving the axial skeleton. In addition, ankylosing spondylitis is associated with increased morbidity and mortality, significantly affecting productivity and overall quality of life. The aim of the present study was to evaluate the cost effectiveness of tofacitinib compared to currently marketed biologic treatment in patients with active ankylosing spondylitis who have responded inadequately to conventional therapy (biologic-naïve population) or previous biologic therapy (biologic-experienced population) in Greece...
December 16, 2023: Clinical Drug Investigation
https://read.qxmd.com/read/38095822/lecanemab-more-questions-than-answers
#30
REVIEW
Upinder Kaur, Jaideep Reddy, Ashutosh Tiwari, Sasanka Chakrabarti, Sankha Shubhra Chakrabarti
The approval of lecanemab by the US Food and Drug Administration has been touted as a defining moment in the treatment of Alzheimer's disease. Lecanemab, an anti-amyloid beta monoclonal antibody, is the first Alzheimer's disease drug targeting amyloid beta that has shown statistically significant cognitive benefits in phase III trials. However, there have been many questions raised over the clinical relevance of the otherwise minimal cognitive improvements. Furthermore, its rapid approval has been mired in controversy, in addition to the reports of adverse events such as amyloid-related imaging abnormalities and several deaths of participants in the lecanemab trials...
December 14, 2023: Clinical Drug Investigation
https://read.qxmd.com/read/38093082/needle-free-jet-injector-assisted-triamcinolone-treatment-of-keloids-and-hypertrophic-scars-is-effective-and-well-tolerated-in-children
#31
JOURNAL ARTICLE
Vazula Zulfra Bekkers, Claire Van Eijsden, Qi Yin, Albert Wolkerstorfer, Errol Prospero Prens, Martijn Bastiaan Adriaan van Doorn
BACKGROUND: Keloids and hypertrophic scars can cause severe pain, pruritus, and psychological distress. Conventional intralesional corticosteroid treatment with needle injections remains challenging, especially in children with needle phobia. OBJECTIVE: We aimed to evaluate the effectiveness, tolerability, and patient satisfaction of intralesional treatment with triamcinolone acetonide using a needle-free electronic pneumatic jet injector in children with keloids and hypertrophic scars...
December 13, 2023: Clinical Drug Investigation
https://read.qxmd.com/read/38041786/comparison-of-the-incidence-of-adverse-events-between-japanese-and-non-japanese-healthy-subjects-in-phase-i-studies-a-systematic-review-and-meta-analysis
#32
Satomi Sakurai, Kazuhiro Matsui, Mamoru Narukawa
BACKGROUND AND OBJECTIVE: Ethnic and racial differences are key factors affecting the results of clinical studies. However, the influence of these factors on the efficacy and safety of medicinal products remains unclear. Race-dependent nature is considered to be one of the factors causing differences in clinical findings, and we investigated its influence on the safety evaluation of drugs. METHODS: We searched PubMed and a Japan drug approval list to find relevant studies, and extracted phase I studies conducted with Japanese and non-Japanese participants using the same protocol and at the same study site...
December 2, 2023: Clinical Drug Investigation
https://read.qxmd.com/read/38006536/clinical-and-laboratory-factors-related-to-seizure-and-serotonin-toxicity-in-tramadol-intoxication-an-egyptian-study
#33
JOURNAL ARTICLE
Ahmed Amin Ali, Mahmoud Mohamed Abdeshafy, Khaled Abdelkawy, Ramy M Elsabaa, Fawzy Elbarbry
BACKGROUND AND OBJECTIVES: Tramadol is a centrally acting analgesic with a lower risk of addiction compared to opioids. Tramadol overdose is becoming a health crisis in Egypt and is associated with serious and severe adverse effects. This study aims to identify clinical and laboratory findings associated with tramadol-induced seizure and serotonin toxicity in adult Egyptian patients with tramadol overdose. METHODS: This prospective study included adult patients admitted for tramadol overdose with or without symptoms of seizure or serotonin toxicity...
December 2023: Clinical Drug Investigation
https://read.qxmd.com/read/37940831/monotherapy-versus-combination-therapy-in-the-treatment-of-painful-diabetic-neuropathy-a-systematic-review-and-meta-analysis
#34
Julyana Medeiros Dantas, Mariana de Jesus Oliveira, Luciana Alves Oliveira Silva, Sávio Batista, Caroline Serafim Dagostin, Daniel Campinho Schachter
BACKGROUND AND OBJECTIVE: Painful peripheral neuropathy is a common and challenging complication of diabetes mellitus. Combination therapy is used widely by clinicians, although strong evidence for efficacy and safety is lacking. The goal of this study is to compare the efficacy and safety of combination versus monotherapy of first-line medications for peripheral diabetic neuropathy. METHODS: PubMed, Embase, Cochrane Central, and clinicaltrials.gov databases were searched on December 5, 2022, for randomized clinical trials comparing combined therapy with gabapentinoids and either tricyclic antidepressants (TCAs) or serotonin and norepinephrine reuptake inhibitors (SNRIs) versus monotherapy with any of these drugs...
December 2023: Clinical Drug Investigation
https://read.qxmd.com/read/37938535/glucagon-like-peptide-1-receptor-agonist-and-risk-of-diabetic-retinopathy-in-patients-with-type-2-diabetes-mellitus-a-systematic-review-and-meta-analysis-of-randomized-placebo-controlled-trials
#35
Xiaojuan Jiao, Ping Peng, Qin Zhang, Yunfeng Shen
BACKGROUND: Glucagon-like peptide 1 receptor agonists (GLP-1RAs) exhibit glucose-lowering, weight-reducing, and blood pressure-lowering effects. Nevertheless, a debate exists concerning the association between GLP-1RA treatment and the risk of diabetic retinopathy (DR) in patients diagnosed with type 2 diabetes mellitus (T2DM). OBJECTIVE: To ascertain the risk of DR in patients with T2DM undergoing GLP-1RA treatment, we conducted a meta-analysis utilizing data derived from randomized placebo-controlled studies (RCTs)...
December 2023: Clinical Drug Investigation
https://read.qxmd.com/read/38017349/characterization-of-the-pharmacokinetics-and-mass-balance-of-a-single-oral-dose-of-trofinetide-in-healthy-male-subjects
#36
JOURNAL ARTICLE
Mona Darwish, Rene Nunez, James M Youakim, Philmore Robertson
BACKGROUND AND OBJECTIVE: Trofinetide is the first drug to be approved for the treatment of Rett syndrome, a neurodevelopmental disorder. The purpose of the study is to fully characterize the metabolic and excretion profiles of trofinetide in humans. METHODS: This Phase 1, open-label, single-dose trial conducted in healthy male adults was designed to characterize the pharmacokinetics of trofinetide (absorption, metabolism, and excretion), mass balance of [14 C]-trofinetide, and safety profile of trofinetide following administration of an oral 12-g dose administered as a mixture of trofinetide and [14 C]-trofinetide...
November 28, 2023: Clinical Drug Investigation
https://read.qxmd.com/read/38015415/acknowledgement-to-referees
#37
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
November 28, 2023: Clinical Drug Investigation
https://read.qxmd.com/read/37995087/safety-concerns-with-nusinersen-risdiplam-and-onasemnogene-abeparvovec-in-spinal-muscular-atrophy-a-real-world-pharmacovigilance-study
#38
JOURNAL ARTICLE
Wei Zhuang, Mei Lu, Ye Wu, Zhehui Chen, Minying Wang, Xudong Wang, Shaoxing Guan, Wanlong Lin
BACKGROUND AND OBJECTIVE: Spinal muscular atrophy (SMA) is a genetic disorder with limited treatment options. It is crucial to have a comprehensive understanding of drug safety in order to make informed clinical drug selections for patients with SMA. Assessing the safety profiles of therapeutic drugs for SMA has been challenging due to the limited number of patients included in clinical trials. This study aims to investigate and compare the potential safety concerns associated with three leading SMA therapeutic drugs: nusinersen, risdiplam, and onasemnogene abeparvovec...
November 23, 2023: Clinical Drug Investigation
https://read.qxmd.com/read/37991687/correction-pharmacokinetics-and-safety-of-erenumab-after-a-single-subcutaneous-injection-dose-in-healthy-chinese-subjects
#39
Qi Shen, Ying Jin, Xiangjie Di, Chao Hu, Runhan Liu, Ying Wang, Xiaohui Qi, Yongsheng Wang, Zhenlei Wang
No abstract text is available yet for this article.
November 22, 2023: Clinical Drug Investigation
https://read.qxmd.com/read/37975961/is-alpelisib-plus-fulvestrant-cost-effective-for-treating-pik3ca-mutation-hr-her2-advanced-breast-cancer-in-the-usa
#40
JOURNAL ARTICLE
Wenhua Wu, Huiting Lin, Jiaqin Cai, Hong Sun, Jia Liu, Congting Hu, Xiaoxia Wei
BACKGROUND AND OBJECTIVE: There is a considerable survival benefit of alpelisib in patients with PIK3CA-mutated, hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- ABC), yet the financial burden may limit its use. Therefore, this study evaluated the cost-effectiveness of alpelisib plus fulvestrant in patients with PIK3CA-mutated, HR+/HER2- ABC in the USA. METHODS: A Markov model was constructed to simulate the progression of PIK3CA-mutated, HR+/HER2- ABC...
November 17, 2023: Clinical Drug Investigation
journal
journal
32205
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.